Xilio Therapeutics
Waltham · Founded 2016
About Xilio Therapeutics
Xilio Therapeutics is a biotechnology company. They offer cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Their tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects.
Company Facts
- Founded: 2016
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $370.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2026)
- Ticker: nasdaq:XLO
- Website: https://www.xiliotx.com
- Phone: +1 617 430 4680
Industries & Categories
Biopharma, Biotechnology, Health Care, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/xilio-therapeutics-111729 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.